The partnership of French drugmaker Sanofi S.A. (Sanofi) and Britain’s GlaxoSmithKline Plc (GSK) entered the global race for finding a COVID-19 vaccine as they declared to have started a human trial of their vaccine on Thursday, September 3, 2020.
As explained by the press release by Sanofi, the clinical trial is currently in Phase 1/2 study and the result is expected by December this year.These two world’s leading drug makers have signed a letter of intent to enter into a collaboration in mid-April 2020 to develop an adjuvanted COVID-19 vaccine, by combining their innovative technologies.
On July 31, Sanofi and GSK announced a collaboration with the United States (U.S.) government to supply up to 100 million doses of their COVID-19.
Read more on toopanda.com